Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × acalabrutinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 48 Other hematologic neoplasm 31 Plasma cell 3 Gastrointestinal 2 Thoracic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 CNS 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 163 Prednisone 129 enzalutamide 124 Docetaxel 121 Abiraterone Acetate 94 Nivolumab 93 Gemcitabine 70 Sunitinib 67 atezolizumab 49 Leuprolide 49 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48 Cisplatin 47 abiraterone 46 Sorafenib 39 radium Ra 223 dichloride 38 Ipilimumab 37 Carboplatin 37 darolutamide 36 apalutamide 36 Everolimus 33 Prednisolone 32 avelumab 31 Axitinib 31 pazopanib 30 cabozantinib 30 Bevacizumab 30 Paclitaxel 29 bicalutamide 28 enfortumab vedotin 27 Cyclophosphamide 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351739 2019-09-10

KEYNOTE143

Acerta Pharma BV

Phase 2 Completed

78 enrolled 10 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡